GlassScriptPhysician profile
David R Shober
NPI 1255319042
$11,885.34
in general payments reported to CMS, 2019-2025
48 companies · $2,544 in 2025
The $2,544 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $785 · 2020: $429 · 2021: $1,600 · 2022: $2,262 · 2023: $2,149 · 2024: $2,117 · 2025: $2,544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,800 · Education: $10.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,800.48 |
| Education | $10.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,515.00 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,446.81 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,318.90 | 2019-2025 | Arexvy, Nucala, Shingrix |
| Abbvie INC. | $1,007.93 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Amarin Pharma, INC. | $953.72 | 2019-2023 | |
| Pfizer INC. | $550.51 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $542.11 | 2022-2025 | |
| Lilly USA, LLC | $516.33 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $485.37 | 2019-2025 | Jardiance, Ofev |
| Amgen INC. | $405.29 | 2019-2025 | Otezla, Repatha, Otezla |
| Genzyme Corporation | $325.43 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $232.02 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Azurity Pharmaceuticals, INC. | $193.20 | 2023-2025 | Horizant, Edarbi, Edarbi |
| Phathom Pharmaceuticals, INC. | $187.41 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $180.35 | 2022-2025 | Camzyos, Eliquis |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Shober listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.